Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Deferred Revenue (2018)

Historic Current Deferred Revenue for Anika Therapeutics (ANIK) over the last 7 years, with Q3 2018 value amounting to $52000.0.

  • Anika Therapeutics' Current Deferred Revenue changed N/A to $52000.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $52000.0, marking a year-over-year change of. This contributed to the annual value of $24510.0 for FY2014, which is 9890.35% down from last year.
  • Latest data reveals that Anika Therapeutics reported Current Deferred Revenue of $52000.0 as of Q3 2018.
  • In the past 5 years, Anika Therapeutics' Current Deferred Revenue ranged from a high of $139535.0 in Q1 2015 and a low of $12885.0 during Q3 2014
  • Moreover, its 3-year median value for Current Deferred Revenue was $35938.0 (2015), whereas its average is $48299.0.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 9898.8% in 2014, then skyrocketed by 20064.42% in 2015.
  • Quarter analysis of 3 years shows Anika Therapeutics' Current Deferred Revenue stood at $24510.0 in 2014, then soared by 38.51% to $33948.0 in 2015, then skyrocketed by 53.18% to $52000.0 in 2018.
  • Its Current Deferred Revenue was $52000.0 in Q3 2018, compared to $74000.0 in Q2 2018 and $33948.0 in Q3 2015.